5|1|Public
5000|$|... <b>moramide</b> <b>intermediate</b> (2-methyl-3-morpholino-1,1-diphenylpropane {{carboxylic}} acid) ...|$|E
50|$|<b>Moramide</b> <b>intermediate</b> {{is listed}} {{separately}} as a Schedule II Narcotic controlled substance (ACSCN 9802), {{also with a}} zero quota.|$|E
50|$|<b>Moramide</b> <b>intermediate</b> (3-methyl-4-morpholin-4-yl-2,2-diphenylbutanoic acid, on INCB Yellow List as 2-methyl-3-morpholino-1,1-diphenylpropane {{carboxylic}} acid) is a moramide precursor scheduled by UN Single Convention on Narcotic Drugs.|$|E
5000|$|<b>Moramides,</b> their <b>intermediates,</b> salts, {{derivatives}} and salts of intermediates and derivatives including: ...|$|R
50|$|In the United States, <b>moramide</b> <b>intermediate</b> is {{designated}} as a Schedule II controlled substance, and has an ACSCN of 9802. The 2014 annual manufacturing quota was nil.|$|E
5000|$|The only European {{countries}} that now use the brand palfium are the Netherlands, Ireland and Luxembourg. It is presumably {{able to be}} imported into other Schengen zone countries under Title 76 of said treaty coming into force in 2002. It is a Schedule I Narcotic controlled substance in the United States, with a DEA ACSCN of 9613 and an annual aggregate manufacturing quota of zero as of 2013, and {{had been out of}} use in the United States for around a decade when the new Controlled Substances Act 1970 was promulgated. The salts of dextromoramide in use are the hydrochloride (free base conversion ratio 0.915) and tartrate (0.724). [...] Racemoramide and <b>moramide</b> <b>intermediate</b> are also controlled.|$|E

